MARKET OUTLOOK The treatment of Crohn’s disease (CD) includes not only conventional therapies, many of which are generically available, but also potent biologics, which are often reserved for…
Introduction: NASH is characterized by a buildup of excess lipid (steatosis) in the liver, resulting in inflammation and eventually liver damage, leading to fibrosis and subsequently cirrhosis and…
Drug treatment of glaucoma focuses on reducing/controlling intraocular pressure and preserving visual function. Given the availability of multiple drug classes—i.e., prostaglandin analogues, beta…
Ulcerative colitis (UC) patients, particularly those with more mild disease activity, will be prescribed a conventional therapy (e.g., 5-ASAs) as first-line treatment; there are multiple generics…
MARKET OUTLOOK Treatment of rheumatoid arthritis (RA) is typically initiated with cost-effective conventional DMARDs, such as methotrexate. For RA patients who are refractory to conventional…
Facing a dramatic rise in expenditures for cancer therapies, U.S. healthcare payers are increasingly assessing the value of drugs relative to their prices, taking into account attributes such as…
Osteoarthritic (OA) pain represents the second-largest segment of the overall chronic pain market, affecting more than 70 million patients with OA in the G7. The OA pain market represents a…
Market Outlook The dynamics within the LABA/ICS FDC, LAMA, and biological drug classes will continue to shape the U.S. asthma market. The dominance of branded LABA/ICS FDCs (e.g., GSK’s …
In the atopic dermatitis market, topical therapies have been the mainstay of treatment, especially for patients with a mild to moderate form of the disease. Conventional systemic immunosuppressants…
Dermatologists have many years of experience with the tumor necrosis factor-alpha (TNF-α) inhibitors Humira (AbbVie) and Enbrel (Pfizer) as first-line biologics for the treatment of psoriasis…
The lucrative EU5 rheumatoid arthritis market is dominated by biologics, including five tumor necrosis factor (TNF)-α inhibitors and four biologics with alternative mechanisms of action. The TNF…
Atopic dermatitis (AD) is a chronic, pruritic inflammatory skin disease that usually affects children but can persist or start in adulthood. For many years, the treatment landscape has remained…
The algorithms for treating psoriatic arthritis (PsA) are unique among rheumatic diseases because most PsA patients receive prior treatment by dermatologists for psoriasis, with many of the same…
Abstract: The mature rheumatoid arthritis (RA) market boasts ten different biologics representing several distinct drug classes, including blockbuster tumor necrosis factor alpha (TNF-α)…
MARKET OUTLOOK The U.S. ulcerative colitis (UC) and Crohn’s disease (CD) markets include the predominantly entrenched TNF-α inhibitors (e.g., Janssen/Merck’s Remicade, AbbVie/Eisai’s Humira…